Global Human Coagulation Factor VIII Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

Global Human Coagulation Factor VIII Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030


Summary

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

According to APO Research, The global Human Coagulation Factor VIII market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

North American market for Human Coagulation Factor VIII is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Human Coagulation Factor VIII is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Human Coagulation Factor VIII is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Human Coagulation Factor VIII is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Human Coagulation Factor VIII include Shire (Baxter), Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk and Greencross, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Human Coagulation Factor VIII, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Human Coagulation Factor VIII, also provides the sales of main regions and countries. Of the upcoming market potential for Human Coagulation Factor VIII, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Coagulation Factor VIII sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Human Coagulation Factor VIII market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Human Coagulation Factor VIII sales, projected growth trends, production technology, application and end-user industry.

Human Coagulation Factor VIII segment by Company

Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Human Coagulation Factor VIII segment by Type

Recombinant Factor VIII
Plasma-derived Factor VIII
Human Coagulation Factor VIII segment by Application

Hemophilia A
Spontanous / Trauma
Surgical
Other
Human Coagulation Factor VIII segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Human Coagulation Factor VIII status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Human Coagulation Factor VIII market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Human Coagulation Factor VIII significant trends, drivers, influence factors in global and regions.
6. To analyze Human Coagulation Factor VIII competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Coagulation Factor VIII market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Coagulation Factor VIII and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Coagulation Factor VIII.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Coagulation Factor VIII market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2019-2030).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Coagulation Factor VIII industry.
Chapter 3: Detailed analysis of Human Coagulation Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Human Coagulation Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Human Coagulation Factor VIII in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Human Coagulation Factor VIII Sales Value (2019-2030)
1.2.2 Global Human Coagulation Factor VIII Sales Volume (2019-2030)
1.2.3 Global Human Coagulation Factor VIII Sales Average Price (2019-2030)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Human Coagulation Factor VIII Market Dynamics
2.1 Human Coagulation Factor VIII Industry Trends
2.2 Human Coagulation Factor VIII Industry Drivers
2.3 Human Coagulation Factor VIII Industry Opportunities and Challenges
2.4 Human Coagulation Factor VIII Industry Restraints
3 Human Coagulation Factor VIII Market by Company
3.1 Global Human Coagulation Factor VIII Company Revenue Ranking in 2023
3.2 Global Human Coagulation Factor VIII Revenue by Company (2019-2024)
3.3 Global Human Coagulation Factor VIII Sales Volume by Company (2019-2024)
3.4 Global Human Coagulation Factor VIII Average Price by Company (2019-2024)
3.5 Global Human Coagulation Factor VIII Company Ranking, 2022 VS 2023 VS 2024
3.6 Global Human Coagulation Factor VIII Company Manufacturing Base & Headquarters
3.7 Global Human Coagulation Factor VIII Company, Product Type & Application
3.8 Global Human Coagulation Factor VIII Company Commercialization Time
3.9 Market Competitive Analysis
3.9.1 Global Human Coagulation Factor VIII Market CR5 and HHI
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.9.3 2023 Human Coagulation Factor VIII Tier 1, Tier 2, and Tier
3.10 Mergers & Acquisitions, Expansion
4 Human Coagulation Factor VIII Market by Type
4.1 Human Coagulation Factor VIII Type Introduction
4.1.1 Recombinant Factor VIII
4.1.2 Plasma-derived Factor VIII
4.2 Global Human Coagulation Factor VIII Sales Volume by Type
4.2.1 Global Human Coagulation Factor VIII Sales Volume by Type (2019 VS 2023 VS 2030)
4.2.2 Global Human Coagulation Factor VIII Sales Volume by Type (2019-2030)
4.2.3 Global Human Coagulation Factor VIII Sales Volume Share by Type (2019-2030)
4.3 Global Human Coagulation Factor VIII Sales Value by Type
4.3.1 Global Human Coagulation Factor VIII Sales Value by Type (2019 VS 2023 VS 2030)
4.3.2 Global Human Coagulation Factor VIII Sales Value by Type (2019-2030)
4.3.3 Global Human Coagulation Factor VIII Sales Value Share by Type (2019-2030)
5 Human Coagulation Factor VIII Market by Application
5.1 Human Coagulation Factor VIII Application Introduction
5.1.1 Hemophilia A
5.1.2 Spontanous / Trauma
5.1.3 Surgical
5.1.4 Other
5.2 Global Human Coagulation Factor VIII Sales Volume by Application
5.2.1 Global Human Coagulation Factor VIII Sales Volume by Application (2019 VS 2023 VS 2030)
5.2.2 Global Human Coagulation Factor VIII Sales Volume by Application (2019-2030)
5.2.3 Global Human Coagulation Factor VIII Sales Volume Share by Application (2019-2030)
5.3 Global Human Coagulation Factor VIII Sales Value by Application
5.3.1 Global Human Coagulation Factor VIII Sales Value by Application (2019 VS 2023 VS 2030)
5.3.2 Global Human Coagulation Factor VIII Sales Value by Application (2019-2030)
5.3.3 Global Human Coagulation Factor VIII Sales Value Share by Application (2019-2030)
6 Human Coagulation Factor VIII Market by Region
6.1 Global Human Coagulation Factor VIII Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Human Coagulation Factor VIII Sales by Region (2019-2030)
6.2.1 Global Human Coagulation Factor VIII Sales by Region: 2019-2024
6.2.2 Global Human Coagulation Factor VIII Sales by Region (2025-2030)
6.3 Global Human Coagulation Factor VIII Sales Value by Region: 2019 VS 2023 VS 2030
6.4 Global Human Coagulation Factor VIII Sales Value by Region (2019-2030)
6.4.1 Global Human Coagulation Factor VIII Sales Value by Region: 2019-2024
6.4.2 Global Human Coagulation Factor VIII Sales Value by Region (2025-2030)
6.5 Global Human Coagulation Factor VIII Market Price Analysis by Region (2019-2024)
6.6 North America
6.6.1 North America Human Coagulation Factor VIII Sales Value (2019-2030)
6.6.2 North America Human Coagulation Factor VIII Sales Value Share by Country, 2023 VS 2030
6.7 Europe
6.7.1 Europe Human Coagulation Factor VIII Sales Value (2019-2030)
6.7.2 Europe Human Coagulation Factor VIII Sales Value Share by Country, 2023 VS 2030
6.8 Asia-Pacific
6.8.1 Asia-Pacific Human Coagulation Factor VIII Sales Value (2019-2030)
6.8.2 Asia-Pacific Human Coagulation Factor VIII Sales Value Share by Country, 2023 VS 2030
6.9 Latin America
6.9.1 Latin America Human Coagulation Factor VIII Sales Value (2019-2030)
6.9.2 Latin America Human Coagulation Factor VIII Sales Value Share by Country, 2023 VS 2030
6.10 Middle East & Africa
6.10.1 Middle East & Africa Human Coagulation Factor VIII Sales Value (2019-2030)
6.10.2 Middle East & Africa Human Coagulation Factor VIII Sales Value Share by Country, 2023 VS 2030
7 Human Coagulation Factor VIII Market by Country
7.1 Global Human Coagulation Factor VIII Sales by Country: 2019 VS 2023 VS 2030
7.2 Global Human Coagulation Factor VIII Sales Value by Country: 2019 VS 2023 VS 2030
7.3 Global Human Coagulation Factor VIII Sales by Country (2019-2030)
7.3.1 Global Human Coagulation Factor VIII Sales by Country (2019-2024)
7.3.2 Global Human Coagulation Factor VIII Sales by Country (2025-2030)
7.4 Global Human Coagulation Factor VIII Sales Value by Country (2019-2030)
7.4.1 Global Human Coagulation Factor VIII Sales Value by Country (2019-2024)
7.4.2 Global Human Coagulation Factor VIII Sales Value by Country (2025-2030)
7.5 USA
7.5.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.5.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.6 Canada
7.6.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.6.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.7 Germany
7.7.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.7.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.8 France
7.8.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.8.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.9 U.K.
7.9.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.9.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.10 Italy
7.10.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.10.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.11 Netherlands
7.11.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.11.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.12 Nordic Countries
7.12.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.12.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.13 China
7.13.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.13.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.14 Japan
7.14.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.14.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.15 South Korea
7.15.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.15.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.16 Southeast Asia
7.16.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.16.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.17 India
7.17.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.17.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.18 Australia
7.18.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.18.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.19 Mexico
7.19.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.19.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.20 Brazil
7.20.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.20.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.21 Turkey
7.21.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.21.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.22 Saudi Arabia
7.22.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.22.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.22.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
7.23 UAE
7.23.1 Global Human Coagulation Factor VIII Sales Value Growth Rate (2019-2030)
7.23.2 Global Human Coagulation Factor VIII Sales Value Share by Type, 2023 VS 2030
7.23.3 Global Human Coagulation Factor VIII Sales Value Share by Application, 2023 VS 2030
8 Company Profiles
8.1 Shire (Baxter)
8.1.1 Shire (Baxter) Comapny Information
8.1.2 Shire (Baxter) Business Overview
8.1.3 Shire (Baxter) Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.1.4 Shire (Baxter) Human Coagulation Factor VIII Product Portfolio
8.1.5 Shire (Baxter) Recent Developments
8.2 Bayer
8.2.1 Bayer Comapny Information
8.2.2 Bayer Business Overview
8.2.3 Bayer Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.2.4 Bayer Human Coagulation Factor VIII Product Portfolio
8.2.5 Bayer Recent Developments
8.3 CSL
8.3.1 CSL Comapny Information
8.3.2 CSL Business Overview
8.3.3 CSL Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.3.4 CSL Human Coagulation Factor VIII Product Portfolio
8.3.5 CSL Recent Developments
8.4 Pfizer
8.4.1 Pfizer Comapny Information
8.4.2 Pfizer Business Overview
8.4.3 Pfizer Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.4.4 Pfizer Human Coagulation Factor VIII Product Portfolio
8.4.5 Pfizer Recent Developments
8.5 Grifols
8.5.1 Grifols Comapny Information
8.5.2 Grifols Business Overview
8.5.3 Grifols Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.5.4 Grifols Human Coagulation Factor VIII Product Portfolio
8.5.5 Grifols Recent Developments
8.6 Biogen
8.6.1 Biogen Comapny Information
8.6.2 Biogen Business Overview
8.6.3 Biogen Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.6.4 Biogen Human Coagulation Factor VIII Product Portfolio
8.6.5 Biogen Recent Developments
8.7 Octapharma
8.7.1 Octapharma Comapny Information
8.7.2 Octapharma Business Overview
8.7.3 Octapharma Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.7.4 Octapharma Human Coagulation Factor VIII Product Portfolio
8.7.5 Octapharma Recent Developments
8.8 NovoNordisk
8.8.1 NovoNordisk Comapny Information
8.8.2 NovoNordisk Business Overview
8.8.3 NovoNordisk Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.8.4 NovoNordisk Human Coagulation Factor VIII Product Portfolio
8.8.5 NovoNordisk Recent Developments
8.9 Greencross
8.9.1 Greencross Comapny Information
8.9.2 Greencross Business Overview
8.9.3 Greencross Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.9.4 Greencross Human Coagulation Factor VIII Product Portfolio
8.9.5 Greencross Recent Developments
8.10 Kedrion
8.10.1 Kedrion Comapny Information
8.10.2 Kedrion Business Overview
8.10.3 Kedrion Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.10.4 Kedrion Human Coagulation Factor VIII Product Portfolio
8.10.5 Kedrion Recent Developments
8.11 BPL
8.11.1 BPL Comapny Information
8.11.2 BPL Business Overview
8.11.3 BPL Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.11.4 BPL Human Coagulation Factor VIII Product Portfolio
8.11.5 BPL Recent Developments
8.12 Hualan Bio
8.12.1 Hualan Bio Comapny Information
8.12.2 Hualan Bio Business Overview
8.12.3 Hualan Bio Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.12.4 Hualan Bio Human Coagulation Factor VIII Product Portfolio
8.12.5 Hualan Bio Recent Developments
8.13 RAAS
8.13.1 RAAS Comapny Information
8.13.2 RAAS Business Overview
8.13.3 RAAS Human Coagulation Factor VIII Sales, Value and Gross Margin (2019-2024)
8.13.4 RAAS Human Coagulation Factor VIII Product Portfolio
8.13.5 RAAS Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Human Coagulation Factor VIII Value Chain Analysis
9.1.1 Human Coagulation Factor VIII Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Human Coagulation Factor VIII Sales Mode & Process
9.2 Human Coagulation Factor VIII Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Human Coagulation Factor VIII Distributors
9.2.3 Human Coagulation Factor VIII Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings